Orthobiologics are materials which originate in the human body and are used to heal injuries and wounds such as ligaments, injured muscles, and broken bones. The high amount of orthobiologics present in the body help in boosting the healing process. The earlier recovery procedure, decrease in number hospital visits, and enhanced healing processes are the welfares through which orthobiologics market is getting significant prominence. Some of the orthobiologics are stem cells, autologous blood, platelet rich plasma, bone grafts, growth factors, and autologous conditioned serum.
The global orthobiologics market is driven by the factors such as increasing cases of bone injuries including sports accidents and road injuries and the growing demand for orthobiologics treatments. According to World Health Organization (WHO), 2017, lethal falls due to accidents are the 2nd most important cause of fractures and/or accidental injuries globally causing approximately 640,000 individuals death cases owing to fatal injuries. Thus, growing number of accident cases demanding proper and early healing is anticipated to create a highly lucrative environment for growth of the orthobiologics market during the forecast period.
In addition, the key factors driving the growth of the global orthobiologics market are increased awareness among athletes and patients. Also, rapidly aging population along with the rise in obesity rate, and an increase in road accidents & sports injuries are another factor propelling the market significantly.
Rising geriatric population, who are highly prone to fractures and injuries due to fragile and delicate skeletal structure, is growing the occurrence of orthopaedic ailments, which in turn, would propel the growth of the orthobiologics market. According to National Institute of Health (NIH), as of 2016 approximately 617 million were aged 65 years and above across the world. The rising geriatric population demanding proper bone care is further anticipated to boost the global market growth. However, the high cost associated with the treatment is expected to become a hurdle for the growth of this market.
The global orthobiologics market is segmented on the basis of product type, application, and end user.
On the basis of product type the global orthobiologics market is segmented into:
On the basis of application, the global orthobiologics market is segmented into:
On the basis of end user, the global orthobiologics market is segmented into:
Geographically, the global orthobiologics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
On the basis of geography, North America region was estimated to dominate the global orthobiologics market. The major market share is owing to extensive research & development efforts and swift expansion of novel products by key players along with the major investors present in North America. In 2015, U.S. based company NuVasive Inc. launched its new bone graft product, AttraX Putty which is used for posterolateral spinal surgery. This product was launched as an autograft extender. Moreover, rising occurrence of injuries and accident cases, continuous developing R&D infrastructure and government support is anticipated to boost the North America orthobiologics market.
However, Asia Pacific is anticipated to make a significant growth in the forecast period. This is majorly due to the high presence of the geriatric population in the region. According to The United Nations Economic and Social Commission for Asia and the Pacific (ESCAP) 2016, in Asia Pacific region 535 million people were 60 years and above in 2015 which is likely expected to reach by 1.3 billion by 2050. Moreover, a high prevalence of accident cases, demand for the orthobiologics product, increased medical tourism, and favourable reimbursement scenario is further anticipated to bolster the market growth in the Asia Pacific.
Key players of global orthobiologics market: